- Anaptys said planned spin-off First Tracks Bio and EcoR1 Capital entered a purchase agreement for a USD 145.0 million private placement of First Tracks Bio common stock.
- First Tracks Bio plans to sell 5,791,478 shares at USD 13.81 per share for USD 80.0 million in gross proceeds.
- EcoR1 Capital plans to sell 4,705,576 shares at USD 13.81 per share.
- Closing is conditioned on completion of the spin-off, which is expected on April 20, 2026.
- Proceeds are intended for general corporate purposes, including clinical development of ANB033.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270900PRIMZONEFULLFEED9679720) on March 27, 2026, and is solely responsible for the information contained therein.